Manish Gopal, MD
Urogynecology and Reconstructive Pelvic Surgery · Somerset, NJNPI 1205981230
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,170 of the $6,543 with a category attached, or 63.7%. 23 manufacturers reported payments, led by Caldera Medical, Inc at 54.3% of the total. Reporting peaked in 2020 at $2,091 and has fallen 74.6% since, to $532 in 2025.
Across 165 payments — averaging $39.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$4K
- Coloplast$589
- Bluewind Medical$582
- Astellas Pharma US Inc$469
- Biotissue Holdings Inc.$315
- Pfizer$288
- plus $749 from 17 others
What the payments were for
- Consulting fees$1,60024%
- Travel & lodging$6009%
- Food & beverage$4,17064%
- Gifts$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 32 | $3,551 |
| Coloplast | 17 | $589 |
| Bluewind Medical | 11 | $582 |
| Astellas Pharma US Inc | 37 | $469 |
| Biotissue Holdings Inc. | 1 | $315 |
| Pfizer | 23 | $288 |
| Sumitomo Pharma America, Inc. | 13 | $202 |
| Boston Scientific | 7 | $194 |
| AbbVie(2 entities) | 6 | $88 |
| Urovant Sciences Inc | 3 | $47 |
| Axonics, Inc. | 2 | $31 |
| Medtronic(2 entities) | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Dentsply IH Inc. | 1 | $17 |
| Millicent US Inc | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $13 |
| Escala Medical Inc. | 1 | $9 |
| Meditrina | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,543 in reported general payments places this provider in the 65th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
See all urogynecology and reconstructive pelvic surgery providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 992 | $625,979 |
| GemtesaVibegron | 168 | $118,826 |
| Estradiol | 994 | $65,886 |
| PremarinEstrogens, Conjugated | 130 | $56,181 |
| Methenamine Hippurate | 594 | $50,059 |
| Mirabegron ErMirabegron | 42 | $26,224 |
| LinzessLinaclotide | 17 | $12,275 |
| Oxybutynin Chloride ErOxybutynin Chloride | 446 | $7,012 |
| Tolterodine Tartrate ErTolterodine Tartrate | 85 | $6,015 |
| Solifenacin Succinate | 50 | $1,977 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 213 | $1,949 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 72 | $1,304 |
| YuvafemEstradiol | 14 | $1,032 |
| Norethindrone Acetate | 20 | $1,009 |
| Lactulose | 46 | $897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $469 | $625,979992 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $202 | $118,826168 claims |
| PfizerPremarin | $288 | $56,181130 claims |
| AbbVieLinzess | $88 | $12,27517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
Other urogynecology and reconstructive pelvic surgery in Somerset
- Nina BhatiaManalapan$77K
- Debra FromerHackensack$50K
- Donald DebrakeleerPennington$36K
- Uzma ChaudhryTrenton$14K
- Alexander BergerCherry Hill$14K
- Kristene WhitmoreCherry Hill$13K
- Betsy GreenleafHowell$11K
- Sandy NosseirMarlton$11K
- Gary MironeCape May Court House$9K
- Anna PancheshnikovVoorhees$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.